[NCI CIRB] A021804 - A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
This study is being done to find out if we can lower the chance of your pheochromocytoma or paraganglioma from growing or spreading by comparing two treatments of olaparib plus temozolomide vs. temozolomide. Also, we hope to find out if this approach is better or worse than the usual approach.
Pheochromocytoma and Paraganglioma
Histologically proven advanced pheochromocytoma or paraganglioma
Prior treatment with other chemotherapy, radiotherapy, or surgery must be completed >28 days prior to registration.
Prior treatment with radiolabeled MIBG must be completed >12 weeks prior to registration.
Prior treatment with antibiotics must be completed >7 days prior to registration.
No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor.
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation.
>18 years of age
Performance status of 0-2
18 - 99
Healthy Volunteers Needed
Duration of Participation
Knight Information Line - email@example.com or 503-494-1080